RxDoctor Payments Data

Adam Cohen, MD

Cardiovascular Disease · Tampa, FLNPI 1205822889

Payments from drug & device makers

$784in general payments, 2019–2025

Across 9 payments — averaging $87.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$260
  • Medtronic$258
  • Boston Scientific$145
  • GSK$82
  • Boehringer Ingelheim$21
  • Impulse Dynamics (USA) Inc.$18

What the payments were for

  • Grants$14518%
  • Food & beverage$61879%
  • Education$213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$784 in reported general payments places this provider in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$122,222
Medicare patients
870
Services billed
1,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$176,246
EntrestoSacubitril/Valsartan68$111,574
Repatha SureclickEvolocumab45$50,180
JardianceEmpagliflozin33$44,650
FarxigaDapagliflozin Propanediol24$33,026
Praluent PenAlirocumab26$19,840
XareltoRivaroxaban12$15,224
Ezetimibe75$3,407
Ranolazine ErRanolazine24$3,099
Nitroglycerin96$2,469
Atorvastatin Calcium219$1,971
Rosuvastatin Calcium160$1,688
Diltiazem 24hr Er (Cd)Diltiazem Hcl37$1,532
Metoprolol Succinate190$1,468
Nebivolol Hcl13$1,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$44,65033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →